Washington Post, April 1, 2008 A new analysis of the American clinical trial process suggests that the system for testing new drugs has routinely excluded or under-represented women, older people, minorities, disabled individuals and rural populations for decades. The article quotes Daniel S. Goldberg, chief policy adviser for the report, and a doctoral student at UTMB. (This article has appeared in numerous media venues.)